ARDX
Ardelyx, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-36/100
Last price
3.30
▼ 0.09 (2.65%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.39
Prev close
3.39
Day high
3.41
Day low
3.23
Volume
5.82M
Market cap
$854.60M
P/E (TTM)
—
52W range
3.23 – 8.40
Day trading desk
Gap from prior close
-0.00%
Prior close 3.39
VWAP
3.30
-0.02% from price
Relative volume
3.00×
Unusually busy
Session range
6.79%
3.23 – 3.45
Position in range
32%
Mid range
ATR (14D)
0.13
3.82% of price
Prior day high
3.42
PDH
Prior day low
3.28
PDL
Bid / ask spread
—
Quote not published
Session volume
12.14M
Avg 4.04M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.36%
-4.3%
1M
-12.43%
-13.6%
3M
-39.04%
-43.6%
6M
-44.37%
-62.6%
YTD
-43.22%
-57.5%
1Y
-37.07%
-53.5%
3Y
-18.87%
-101.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARDX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-128.79K
Net selling
Buy transactions
12
332.15K shares
Sell transactions
21
460.93K shares
Net transactions
+33
Buys less sells
Sell : buy shares
1.4 : 1
Mixed
Insider-held shares
7.57M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 21, 26 | BISHOP JOHN E Chief Technology Officer |
SELL | 19.75K | $76.17K | Direct |
| Aug 21, 26 | RAAB MICHAEL G Chief Executive Officer |
SELL | 58.57K | $225.91K | Direct |
| Aug 21, 26 | WILLIAMS LAURA A Officer |
SELL | 10.74K | $41.42K | Direct |
| Aug 21, 26 | KELLIHER MICHAEL Officer |
SELL | 7.76K | $29.92K | Direct |
| Aug 21, 26 | FOSTER ERIC DUANE Officer |
SELL | 8.56K | $33.02K | Direct |
| Aug 21, 26 | BRADY JAMES PARKER Officer |
SELL | 15.14K | $58.38K | Direct |
| Aug 21, 26 | HOHENLEITNER SUSAN Chief Financial Officer |
SELL | 1.56K | $6.01K | Direct |
| Jul 15, 26 | RAAB MICHAEL G Chief Executive Officer |
SELL | 41.67K | $210.92K | Direct |
| Jul 15, 26 | RAAB MICHAEL G Chief Executive Officer |
CONVERSION | 20.83K | $20.63K | Direct |
| Jun 18, 26 | WILLIAMS LAURA A Officer |
SELL | 81.90K | $490.49K | Direct |
| Jun 18, 26 | WILLIAMS LAURA A Officer |
CONVERSION | 31.00K | $30.69K | Direct |
| Jun 16, 26 | BERTRAND WILLIAM C JR Director |
STOCK | 38.80K | $0 | Direct |
| Jun 16, 26 | RODGERS RICHARD J. Director |
STOCK | 26.45K | $0 | Direct |
| Jun 16, 26 | BAZEMORE ROBERT B Director |
STOCK | 26.45K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERTRAND WILLIAM C JR |
Director | 329.51K | Stock Award(Grant) |
BISHOP JOHN E |
Chief Technology Officer | 317.10K | Sale |
FOSTER ERIC DUANE |
Officer | 409.41K | Sale |
KELLIHER MICHAEL |
Officer | 349.66K | Sale |
MOTT DAVID M |
Director | 3.35M | Stock Award(Grant) |
RAAB MICHAEL G |
Chief Executive Officer | 1.65M | Sale |
RENZ JUSTIN ANDREW |
Chief Financial Officer | 409.05K | Sale |
RODGERS RICHARD J. |
Director | 440.00K | Stock Award(Grant) |
ROSENBAUM DAVID PAUL |
Officer | — | Sale |
WILLIAMS LAURA A |
Officer | 367.46K | Sale |
Fundamentals
Market cap$854.60M
Enterprise value$825.49M
Revenue (TTM)$450.89M
Gross profit$338.28M
EBITDA$-32.11M
Net income$-55.70M
EPS (TTM)$-0.23
Free cash flow$20.47M
Total cash$281.83M
Total debt$282.51M
Book value / share$0.60
Shares outstanding258.19M
Float210.66M
Short % of float10.13%
Dividend yield0.00%
Beta (5Y)0.68
Valuation & profitability ratios
Trailing P/E—
Forward P/E11.39
PEG ratio—
Price / sales—
Price / book5.54
EV / revenue1.83
EV / EBITDA-25.71
Gross margin75.02%
Operating margin-10.28%
Profit margin-12.35%
Return on equity-38.61%
Return on assets-4.25%
Debt / equity189.59
Current ratio3.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $407.32M | $333.62M | $124.46M | $52.16M | +22.1% |
| Operating revenue | $407.32M | $333.62M | $124.46M | $52.16M | +22.1% |
| Cost of revenue | $39.54M | $50.56M | $17.80M | $4.12M | -21.8% |
| Gross profit | $367.78M | $283.06M | $106.66M | $48.04M | +29.9% |
| Research & development | $71.53M | $52.32M | $35.54M | $35.20M | +36.7% |
| Selling, general & admin | $337.23M | $258.69M | $134.40M | $76.60M | +30.4% |
| Total operating expense | $408.76M | $311.01M | $169.94M | $111.80M | +31.4% |
| Operating income | -$40.98M | -$27.95M | -$63.28M | -$63.76M | -46.6% |
| Net interest income | -$28.40M | -$20.09M | -$8.87M | -$5.07M | -41.3% |
| Pre-tax income | -$60.63M | -$38.87M | -$65.52M | -$67.20M | -56.0% |
| Tax provision | $969.00K | $266.00K | $547.00K | $8.00K | +264.3% |
| Net income | -$61.60M | -$39.14M | -$66.07M | -$67.21M | -57.4% |
| Net income to common | -$61.60M | -$39.14M | -$66.07M | -$67.21M | -57.4% |
| Basic EPS | -0.26 | -0.17 | -0.30 | -0.42 | -52.9% |
| Diluted EPS | -0.26 | -0.17 | -0.30 | -0.42 | -52.9% |
| EBIT | -$32.23M | -$18.78M | -$56.65M | -$62.13M | -71.7% |
| EBITDA | -$29.17M | -$16.71M | -$55.35M | -$60.98M | -74.6% |
| Basic shares | 241.03M | 235.23M | 219.33M | 158.69M | +2.5% |
| Diluted shares | 241.03M | 235.23M | 219.33M | 158.69M | +2.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $68.00M | $64.93M | $21.47M | $96.14M | — | +4.7% |
| Cash & short-term investments | $264.69M | $250.10M | $184.30M | $123.91M | — | +5.8% |
| Accounts receivable | $71.85M | $57.70M | $22.03M | $7.73M | — | +24.5% |
| Inventory | $17.73M | $21.17M | $12.45M | $3.28M | — | -16.2% |
| Total current assets | $382.32M | $356.45M | $246.11M | $153.60M | — | +7.3% |
| Property, plant & equipment | $6.98M | $3.88M | $6.60M | $10.52M | — | +80.1% |
| Total assets | $501.60M | $435.75M | $297.58M | $190.07M | — | +15.1% |
| Total current liabilities | $88.61M | $77.83M | $50.39M | $65.60M | — | +13.8% |
| Current debt | — | — | — | $26.71M | $32.26M | — |
| Long-term debt | $202.83M | $150.85M | $49.82M | — | — | +34.5% |
| Total debt | $207.95M | $153.44M | $55.98M | $36.46M | — | +35.5% |
| Total liabilities | $334.65M | $262.46M | $130.76M | $91.74M | — | +27.5% |
| Retained earnings | -$946.94M | -$885.34M | -$846.20M | -$780.14M | — | -7.0% |
| Shareholder equity | $166.95M | $173.29M | $166.82M | $98.33M | — | -3.7% |
| Working capital | $293.71M | $278.62M | $195.72M | $88.00M | — | +5.4% |
| Net tangible assets | $166.95M | $173.29M | $166.82M | $98.33M | — | -3.7% |
| Shares issued | 244.35M | 238.02M | 232.45M | 198.58M | — | +2.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$61.60M | -$39.14M | -$66.07M | -$67.21M | -57.4% |
| Depreciation & amortisation | $3.06M | $2.06M | $1.29M | $1.14M | +48.3% |
| Stock-based compensation | $48.96M | $37.38M | $13.53M | $10.75M | +31.0% |
| Change in working capital | -$31.35M | -$49.17M | -$43.39M | -$19.57M | +36.2% |
| Operating cash flow | -$42.48M | -$44.81M | -$89.72M | -$70.04M | +5.2% |
| Capital expenditure | -$1.49M | -$1.01M | -$344.00K | -$55.00K | -47.6% |
| Investing cash flow | -$8.96M | -$18.32M | -$131.25M | $18.41M | +51.1% |
| Financing cash flow | $54.51M | $106.59M | $146.29M | $75.34M | -48.9% |
| Free cash flow | -$43.98M | -$45.82M | -$90.06M | -$70.10M | +4.0% |
| End cash position | $68.00M | $64.93M | $21.47M | $96.14M | +4.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $120.88M | $94.47M | $125.22M | $110.33M | $97.66M | +27.9% |
| Operating revenue | $120.88M | $94.47M | $125.22M | $110.33M | $97.66M | +27.9% |
| Cost of revenue | $5.76M | $4.81M | $10.85M | $3.98M | $12.40M | +19.7% |
| Gross profit | $115.12M | $89.66M | $114.37M | $106.35M | $85.26M | +28.4% |
| Research & development | $26.10M | $20.19M | $22.86M | $18.07M | $15.67M | +29.3% |
| Selling, general & admin | $101.44M | $102.27M | $86.41M | $83.61M | $83.99M | -0.8% |
| Total operating expense | $127.54M | $122.45M | $109.27M | $101.68M | $99.65M | +4.2% |
| Operating income | -$12.43M | -$32.79M | $5.10M | $4.67M | -$14.39M | +62.1% |
| Net interest income | -$6.22M | -$6.92M | -$7.58M | -$7.98M | -$6.58M | +10.0% |
| Pre-tax income | -$16.61M | -$37.60M | -$400.00K | -$867.00K | -$19.08M | +55.8% |
| Tax provision | $110.00K | $8.00K | $7.00K | $102.00K | $1.00K | +1,275.0% |
| Net income | -$16.72M | -$37.60M | -$407.00K | -$969.00K | -$19.08M | +55.5% |
| Net income to common | -$16.72M | -$37.60M | -$407.00K | -$969.00K | -$19.08M | +55.5% |
| Basic EPS | -0.07 | -0.15 | 0.00 | 0.00 | -0.08 | +53.3% |
| Diluted EPS | -0.07 | -0.15 | 0.00 | 0.00 | -0.08 | +53.3% |
| EBIT | -$10.39M | -$30.68M | $7.18M | $7.12M | -$12.50M | +66.1% |
| EBITDA | -$9.78M | -$29.77M | $8.10M | $8.02M | -$11.87M | +67.1% |
| Basic shares | 248.07M | 245.86M | 243.61M | 241.91M | 239.93M | +0.9% |
| Diluted shares | 248.07M | 245.86M | 243.61M | 241.91M | 239.93M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $97.19M | $31.21M | $68.00M | $42.72M | $90.05M | +211.4% |
| Cash & short-term investments | $281.83M | $238.07M | $264.69M | $242.71M | $238.45M | +18.4% |
| Accounts receivable | $100.35M | $82.84M | $71.85M | $76.61M | $62.55M | +21.1% |
| Inventory | $25.86M | $22.75M | $17.73M | $25.17M | $22.27M | +13.7% |
| Total current assets | $441.93M | $381.87M | $382.32M | $367.99M | $351.57M | +15.7% |
| Property, plant & equipment | $5.85M | $6.43M | $6.98M | $7.22M | $7.15M | -9.2% |
| Total assets | $575.89M | $504.51M | $501.60M | $486.17M | $466.77M | +14.1% |
| Total current liabilities | $132.22M | $109.57M | $88.61M | $83.39M | $81.72M | +20.7% |
| Long-term debt | $251.82M | $203.52M | $202.83M | $202.14M | $201.45M | +23.7% |
| Total debt | $256.19M | $208.26M | $207.95M | $207.61M | $206.64M | +23.0% |
| Total liabilities | $426.88M | $355.88M | $334.65M | $331.89M | $327.24M | +19.9% |
| Retained earnings | -$1.00B | -$984.54M | -$946.94M | -$946.53M | -$945.56M | -1.7% |
| Shareholder equity | $149.01M | $148.62M | $166.95M | $154.28M | $139.53M | +0.3% |
| Working capital | $309.71M | $272.30M | $293.71M | $284.60M | $269.85M | +13.7% |
| Net tangible assets | $149.01M | $148.62M | $166.95M | $154.28M | $139.53M | +0.3% |
| Shares issued | 249.15M | 246.97M | 244.35M | 242.97M | 240.77M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$16.72M | -$37.60M | -$407.00K | -$969.00K | -$19.08M | +55.5% |
| Depreciation & amortisation | $604.00K | $915.00K | $921.00K | $905.00K | $631.00K | -34.0% |
| Stock-based compensation | $15.32M | $14.16M | $12.45M | $12.74M | $11.69M | +8.2% |
| Change in working capital | -$6.34M | -$10.38M | $7.67M | -$9.24M | -$18.93M | +38.9% |
| Operating cash flow | -$6.40M | -$32.24M | $20.95M | $365.00K | -$25.34M | +80.2% |
| Capital expenditure | -$13.00K | -$69.00K | -$361.00K | -$156.00K | -$650.00K | +81.2% |
| Investing cash flow | $22.66M | -$9.99M | $3.78M | -$50.51M | $34.92M | +326.7% |
| Financing cash flow | $49.72M | $5.44M | $557.00K | $2.81M | $49.66M | +813.6% |
| Free cash flow | -$6.41M | -$32.31M | $20.59M | $209.00K | -$25.99M | +80.2% |
| End cash position | $97.19M | $31.21M | $68.00M | $42.72M | $90.05M | +211.4% |
Options analytics
Put / call volume
0.35
Call-heavy session
Put / call open interest
0.19
Positioning, not flow
Max pain
9.00
+171.9% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
286
Contracts, this expiry
Put volume
99
Contracts, this expiry
Heaviest call OI
11.00
25 contracts
Heaviest put OI
9.00
5 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.05 | -0.07 | -41.4% |
| Mar 2026 | -0.14 | -0.15 | -5.0% |
| Dec 2025 | 0.01 | 0.00 | -100.0% |
| Sep 2025 | -0.07 | 0.00 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.02 | 8 | $129.03M | +17.0% |
| Next quarter | 0.04 | 8 | $144.33M | +15.3% |
| Current year | -0.19 | 8 | $488.72M | +20.0% |
| Next year | 0.29 | 8 | $624.07M | +27.7% |
Analyst targets & ownership
Mean target$12.90
High target$18.00
Low target$8.00
Implied upside290.91%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders3.04%
Held by institutions73.23%
Institutions holding329
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.40
-2.91% from price
SMA 20
3.46
-4.36% from price
SMA 50
3.89
-14.83% from price
SMA 100
4.76
-30.68% from price
SMA 200
5.61
-41.00% from price
EMA 12
3.41
-3.36% from price
EMA 26
3.57
-7.51% from price
EMA 50
3.92
-15.74% from price
RSI (14)
31.9
Neutral
MACD (12,26,9)
-0.15
Hist 0.02
ATR (14)
0.13
3.80% of price
Realised vol 30D
28.5%
Annualised
Bollinger upper
3.69
20, 2σ
Bollinger lower
3.23
20, 2σ
50 / 200 cross
Death
3.89 vs 5.61
Trend bias
Below 200
-41.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.83
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
28.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.6%
Peak to trough
Max drawdown 5Y
-70.0%
Peak to trough
ATR 14
0.13
3.80% of price
Beta (reported)
0.68
5Y monthly, from filing
Short interest
Shares short
25.60M
Prior 22.43M
Change vs prior
+14.1%
Shorts adding
% of float
10.13%
Elevated
% of shares out
9.92%
Against total outstanding
Days to cover
6.6
Crowded exit
Float
210.66M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 18, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 10, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 7, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 7, 26 | BTIG | MAINTAINED | Buy | Buy |
| Feb 23, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Feb 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 20, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 29, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 21, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jan 9, 26 | Citigroup | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-17
Offering Registrations
S-8 · 2026-08-10
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-17
Proxy Statements
DEFA14A · 2026-05-26
Proxy Statements
DEFA14A · 2026-05-19
Periodic Financial Reports
10-Q · 2026-04-30
Headlines
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
GlobeNewswire · 2d ago
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
GlobeNewswire · 7d ago
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
MarketBeat · 16d ago
Hyperphosphatemia Market Insight, Epidemiology, and Market Forecast to 2036 Now Available — See Which Novel Mechanism Could Unseat Sevelamer as Phosphate Binders Face a Pill-Burden Reckoning
GlobeNewswire · 29d ago
Ardelyx to Participate in Upcoming Investor Conferences
GlobeNewswire · 36d ago
Ardelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats Up
Simply Wall St. · 46d ago
Valeris Welcomes Patient Services Veteran Lauren Cole to Lead Commercial Strategy
PR Newswire · 50d ago
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.